OTC:ELTP
ELITE PHARMACEUTICALS INC /NV/
ELTP is a growth-stage biopharmaceutical firm focused on innovative therapies for specialized therapeutic areas with significant R&D investment.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted to ELTP due to its aggressive top-line growth trajectory, doubling revenue annually over the last three years. The company's heavy investment in R&D ($8.0M) positions it for potential blockbuster drug approvals that could transform its valuation from a loss-making entity to a profitable market leader.
Bear Case
The stock carries high risk given the massive retained earnings deficit of $120.7M and negative net income trends suggesting underlying business model sustainability issues. Current liabilities exceed current assets significantly when adjusting for non-cash items, raising concerns about short-term solvency without external financing or consistent profitability.
About ELITE PHARMACEUTICALS INC /NV/
ELITE PHARMACEUTICALS INC develops and commercializes proprietary pharmaceutical products primarily serving the oncology and rare disease markets. The company generates revenue through product sales, licensing agreements, and strategic partnerships within the competitive global healthcare sector.
Analysis
Management Discussion
While the company successfully increased revenue from $34.2M in 2023 to $84.0M in 2025, recent financials show a sharp decline in profitability with a net loss of $4.3M and negative cash flow from operations adjustments. The substantial increase in accounts receivable by nearly $10M relative to the prior year warrants close monitoring for collection efficiency and potential bad debt provisions.
Industry Overview
The global pharmaceutical industry is characterized by high barriers to entry, intense competition from established giants, and rapid technological advancements in drug discovery. Companies must navigate complex regulatory landscapes while managing long development cycles and uncertain return on investment profiles for new therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $34.2M | $56.6M | $84.0M |
| Cost of Revenue | $17.6M | $30.3M | $44.0M |
| Gross Profit | $16.6M | $26.4M | $40.1M |
| Operating Expenses | $12.9M | $15.6M | $20.5M |
| Operating Income | $3.7M | $10.8M | $19.6M |
| R&D | $6.2M | $6.9M | $8.0M |
| G&A | $5.1M | $7.1M | $9.0M |
| Stock-Based Comp | $39.3K | $159.9K | $227.6K |
| D&A | $1.3M | $1.3M | $1.2M |
| Depreciation | $1.2M | $1.3M | $1.2M |
| Other OpEx | $1.6M | $1.5M | $3.5M |
| Non-Operating Income | $309.9K | $-10.3M | $-19.7M |
| Interest Expense | $1.1M | $588.6K | — |
| Interest Income | $7.5K | $20.9K | $20.9K |
| Pre-Tax Income | $4.0M | $463.1K | $-52.1K |
| Income Tax | $424.0K | $-19.6M | $4.3M |
| Continuing Ops | $3.6M | $20.1M | $-4.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $3.6M | $20.1M | $-4.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $3.6M | $20.1M | $-4.3M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $21.5M | $40.0M | $57.7M |
| Cash & Equivalents | $7.8M | $7.1M | — |
| Accounts Receivable | $3.1M | $19.5M | $29.2M |
| Inventory | $9.6M | $12.9M | $16.2M |
| Prepaid Expenses | $1.0M | $524.2K | $976.4K |
| Other Current Assets | $0 | $0 | $11.3M |
| Long-Term Assets | $19.4M | $43.6M | $38.6M |
| PP&E (Net) | $10.4M | $10.2M | $10.3M |
| Operating Leases | $13.1K | $2.4M | $2.0M |
| Other LT Assets | $8.9M | $31.1M | $26.3M |
| Total Assets | $40.9M | $83.7M | $96.4M |
| Current Liabilities | $7.8M | $13.0M | $11.8M |
| Accounts Payable | $2.4M | $2.7M | $3.0M |
| Current Leases | $14.9K | $411.4K | $472.4K |
| Deferred Revenue | $13.3K | $13.3K | $5.6K |
| Taxes Payable | $415.0K | $485.3K | $340.6K |
| Other Current Liab | $-104.1K | $4.1M | $4.3M |
| Long-Term Liabilities | $4.1M | $13.0M | $31.0M |
| LT Operating Leases | — | $2.0M | $1.6M |
| Other LT Liab | $4.1M | $11.1M | $29.5M |
| Total Liabilities | $11.9M | $26.1M | $42.9M |
| Shareholders' Equity | $29.0M | $57.6M | $53.5M |
| Paid-In Capital | $164.8M | $173.2M | $173.5M |
| Retained Earnings | $-136.5M | $-116.4M | $-120.7M |
| Treasury Stock | $306.8K | $306.8K | $306.8K |
| Total L&E | $40.9M | $83.7M | $96.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $3.6M | $20.1M | $-4.3M |
| Non-Cash Adjustments | $-4.8M | $-50.6M | $-689 |
| Working Capital Changes | $4.5M | $27.2M | $11.8M |
| Cash from Operations | $3.3M | $-3.3M | $7.5M |
| Capital Expenditures | $5.7M | $809.7K | $1.6M |
| Cash from Investing | $-5.7M | $-809.7K | $-2.4M |
| Cash from Financing | $1.7M | $3.4M | $-825.7K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-695.7K | $-705.6K | $4.2M |
| Beginning Cash | $8.9M | $8.2M | $7.5M |
| Ending Cash | $8.2M | $7.5M | $11.8M |
Frequently Asked Questions
How does ELITE PHARMACEUTICALS INC /NV/ make money?
Primary revenue streams include direct sales of proprietary drug products, commercialization partnerships with major pharmaceutical entities, and licensing fees for intellectual property rights. Secondary segments involve grant-funded research initiatives and potential royalties from milestone-based agreements.
What are the main risks for ELTP?
Significant operating losses and a substantial retained earnings deficit indicate potential liquidity constraints if revenue growth does not stabilize profitability. High research and development expenditures coupled with volatile accounts receivable suggest exposure to reimbursement delays or market adoption issues. The pharmaceutical industry faces stringent regulatory scrutiny and high clinical trial failure rates that could impact future product launches.
What is ELTP's competitive advantage?
The company leverages a robust pipeline of novel molecular entities targeting unmet medical needs in oncology. A strong patent portfolio provides regulatory exclusivity periods that protect market share against generic competition. Strategic alliances with large pharmaceutical companies reduce commercialization risk and accelerate time-to-market for new therapies.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.